衛采擴建英國專業藥物製造廠
Eisai expands UK manufacturing facility for specialized medicines
Updated at: June 15, 2026 at 09:00 AM
衛材製藥是一家知名的製藥公司，已顯著擴大其位於赫特福郡哈特菲爾德的製造廠，鞏固了其作為重要全球供應樞紐的地位。
Eisai, a prominent pharmaceutical company, has significantly expanded its manufacturing facility in Hatfield, Hertfordshire, cementing its position as a vital global supply hub.
作為歐中非地區的總部，該廠區在整合專門藥物的研發、生產與行銷方面發揮了關鍵作用。
Serving as the headquarters for EMEA, the site plays a critical role in integrating discovery, production, and marketing for specialized medicines.
透過策略投資，該公司已轉型其在英國的佈局，以更好地滿足全球對治療方案日益增長的需求，特別是針對晚期癌症和神經退化疾病。
Through strategic investments, the company has transformed its UK presence to better address the growing global demand for treatments, particularly for advanced cancers and neurological disorders.
2013年至2014年間的一項800萬英鎊的重大擴建引入了針對Lenvima和Fycompa等藥物的專門包裝能力。
A major £8 million expansion in 2013-2014 introduced specialized packaging capabilities for drugs like Lenvima and Fycompa.
隨後在2020年投資1150萬英鎊，增設了先進的高科技包裝產線，將產能提升至三倍。
This was followed by an £11.5 million investment in 2020, which installed advanced, high-tech packaging lines to triple production output.
這些努力是長期目標的一部分，旨在2025年前將製造產能提高四倍。
These efforts are part of a long-term goal to increase manufacturing capacity four-fold by 2025.
如今，哈特菲爾德工廠為73個國家提供服務，每年向大約50萬名患者提供超過30種不同的藥物製劑。
Today, the Hatfield plant serves 73 countries, delivering over 30 different product formulations to roughly 500,000 patients annually.
通過創造高技術就業機會並結合尖端技術，衛材對英國的承諾被廣泛稱讚為對該國具有競爭力的生命科學產業投下了重要的信任一票。
By creating highly skilled jobs and incorporating cutting-edge technologies, Eisai’s commitment to the UK has been widely praised as a significant vote of confidence in the nation's competitive life sciences sector.
